Kate McCooey
Medical · Mountain Lakes, NJNPI 1427480292
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 317 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations.
Across 317 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$491
- Novartis$488
- E.r. Squibb & Sons, L.L.C.$472
- AstraZeneca$425
- GSK$356
- Johnson & Johnson$300
- plus $3K from 45 others
What the payments were for
- Food & beverage$5,27599%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$109
How this compares
$5,340 in reported general payments places this provider in the 85th percentile of 573 medical providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neulasta OnproPegfilgrastim | 59 | $368,240 |
| JakafiRuxolitinib Phosphate | 19 | $315,901 |
| ProcritEpoetin Alfa | 84 | $267,621 |
| SprycelDasatinib | 12 | $258,864 |
| BrukinsaZanubrutinib | 18 | $249,082 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 15 | $234,229 |
| RevlimidLenalidomide | 16 | $231,011 |
| NeulastaPegfilgrastim | 19 | $151,400 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 21 | $143,555 |
| Lupron DepotLeuprolide Acetate | 21 | $68,702 |
| XareltoRivaroxaban | 48 | $46,618 |
| EliquisApixaban | 56 | $39,033 |
| Palonosetron Hcl | 22 | $3,163 |
| Anastrozole | 63 | $1,222 |
| Hydroxyurea | 38 | $791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $228 | $315,90119 claims |
| Johnson & JohnsonProcrit, Xarelto | $300 | $314,239132 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $472 | $258,86412 claims |
| Bristol Myers SquibbRevlimid | $92 | $231,01116 claims |
| AmgenNeulasta | $134 | $151,40019 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $17 | $143,55521 claims |
| AbbVieLupron Depot | $64 | $68,70221 claims |
| PfizerEliquis | $81 | $39,03356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 573 medical providers in New Jersey.
Other medical in Mountain Lakes
- Shannon WelnerVerona$176K
- Christinna DelgenioColts Neck$114K
- Anita FoxVerona$17K
- Therese CasasKinnelon$16K
- Joseph CollettiLinwood$16K
- Melissa MiaoKearny$14K
- Gabriela Plesek-AndiaVerona$13K
- Stephanie PhillipsMarlton$12K
- Sean AdairCape May Court House$12K
- Shane CourtneyLinwood$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.